AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
Log in

NASDAQ:FATEFate Therapeutics Stock Price, Forecast & News

$30.88
-1.09 (-3.41 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$30.86
Now: $30.88
$32.49
50-Day Range
$26.59
MA: $30.08
$35.23
52-Week Range
$12.59
Now: $30.88
$37.24
Volume602,800 shs
Average Volume1.08 million shs
Market Capitalization$2.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Read More
Fate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.68 million
Book Value$3.24 per share

Profitability

Net Income$-98,150,000.00
Net Margins-1,059.44%

Miscellaneous

Employees104
Market Cap$2.40 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

How has Fate Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 29.8% and is now trading at $30.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fate Therapeutics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fate Therapeutics.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Fate Therapeutics.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics Inc (NASDAQ:FATE) announced its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.05. The biopharmaceutical company earned $2.52 million during the quarter, compared to the consensus estimate of $1.69 million. Fate Therapeutics had a negative net margin of 1,059.44% and a negative return on equity of 52.08%. The business's revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.30) EPS. View Fate Therapeutics' earnings history.

What price target have analysts set for FATE?

17 brokerages have issued 1-year target prices for Fate Therapeutics' shares. Their forecasts range from $25.00 to $57.00. On average, they anticipate Fate Therapeutics' share price to reach $35.88 in the next twelve months. This suggests a possible upside of 16.2% from the stock's current price. View analysts' price targets for Fate Therapeutics.

Has Fate Therapeutics been receiving favorable news coverage?

Media headlines about FATE stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fate Therapeutics earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutFate Therapeutics.

Who are some of Fate Therapeutics' key competitors?

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Juno Therapeutics (JUNO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Exelixis (EXEL), Gilead Sciences (GILD), TG Therapeutics (TGTX) and Clovis Oncology (CLVS).

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:
  • J. Scott Wolchko, President, Chief Executive Officer & Director
  • Daniel D. Shoemaker, Chief Scientific Officer
  • Yu Waye Chu, Vice President-Clinical Development
  • Jim Beitel, Senior Vice President-Corporate Development
  • Bahram Valamehr, Chief Development Officer

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.36%), Victory Capital Management Inc. (4.58%), Victory Capital Management Inc. (4.58%), Janus Henderson Group PLC (4.34%), State Street Corp (3.25%) and Franklin Resources Inc. (1.51%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View institutional ownership trends for Fate Therapeutics.

Which major investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Pictet Asset Management Ltd., Franklin Resources Inc., Sofinnova Investments Inc., Morgan Stanley, Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, and J Scott Wolchko. View insider buying and selling activity for Fate Therapeutics.

Which major investors are buying Fate Therapeutics stock?

FATE stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Federated Hermes Inc., Invesco Ltd., Asymmetry Capital Management L.P., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., and State Street Corp. View insider buying and selling activity for Fate Therapeutics.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $30.88.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $2.40 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.